{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T20:07:32Z","timestamp":1769285252517,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.amjcard.2022.09.011","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T22:05:09Z","timestamp":1665180309000},"page":"S43-S50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S1","title":["Counseling Family Members and Monitoring for Evidence of Disease in Asymptomatic Carriers of Amyloid Transthyretin Cardiac Amyloidosis"],"prefix":"10.1016","volume":"185","author":[{"given":"Naomi","family":"Barker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3407-0248","authenticated-orcid":false,"given":"Daniel P.","family":"Judge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2022.09.011_bib0001","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","article-title":"Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0002","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/mus.20821","article-title":"The molecular biology and clinical features of amyloid neuropathy","volume":"36","author":"Benson","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0003","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0004","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.tcm.2019.12.003","article-title":"Transthyretin cardiac amyloidosis: a treatable form of heart failure with a preserved ejection fraction","volume":"31","author":"Griffin","year":"2021","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0005","unstructured":"Rowczenio D, Wechalekar A. Mutations in hereditary amyloidosis. Available at: http:\/\/amyloidosismutations.com. Accessed on February 2, 2022."},{"key":"10.1016\/j.amjcard.2022.09.011_bib0006","first-page":"253","article-title":"Demonstration einer eigenartigen familiaren Paraamyloidose","volume":"56","author":"Ostertag","year":"1932","journal-title":"Zentrabl Path"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0007","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic V122I transthyretin variant in elderly black Americans","volume":"372","author":"Quarta","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0008","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","article-title":"Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant","volume":"33","author":"Sattianayagam","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0009","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14797\/mdcvj.1066","article-title":"ATTR epidemiology, genetics, and prognostic factors","volume":"18","author":"Obi","year":"2022","journal-title":"Methodist deBakey Cardiovasc J"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0010","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/mus.20644","article-title":"Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal","volume":"35","author":"Concei\u00e7\u00e3o","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0011","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1136\/jmg.2003.014803","article-title":"Common origin of the Val30Met mutation responsible for the amyloidogenic transthyretin type of familial amyloidotic polyneuropathy","volume":"41","author":"Ohmori","year":"2004","journal-title":"J Med Genet"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0012","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1469-1809.2008.00439.x","article-title":"On the origin of the transthyretin Val30Met familial amyloid polyneuropathy","volume":"72","author":"Zaros","year":"2008","journal-title":"Ann Hum Genet"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0013","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000154146","article-title":"Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence","volume":"43","author":"Sousa","year":"1993","journal-title":"Hum Hered"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0014","series-title":"Amyloid and amyloidosis 1998: proceedings of the VIIIth International Symposium on Amyloidosis, August 7-11","first-page":"227","article-title":"The origin of the transthyretin Ile 122 allele: haplotype analysis and population studies","author":"Jacobson","year":"1999"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0015","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3109\/13506129.2013.844689","article-title":"Functional variation of the transthyretin gene among human populations and its correlation with amyloidosis phenotypes","volume":"20","author":"Polimanti","year":"2013","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0016","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/mgg3.231","article-title":"The prevalence and distribution of the amyloidogenic transthyretin (TTR) V122I allele in Africa","volume":"4","author":"Jacobson","year":"2016","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0017","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/jnnp.59.1.45","article-title":"Familial amyloid polyneuropathy (TTR ala 60) in north west Ireland: a clinical, genetic, and epidemiological study","volume":"59","author":"Reilly","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0018","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/13506120209072442","article-title":"Transthyretin Thr60Ala Appalachian-type mutation in a Japanese family with familial amyloidotic polyneuropathy","volume":"9","author":"Kotani","year":"2002","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0019","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1750-1172-9-61","article-title":"THAOS: gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease","volume":"9","author":"Wixner","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0020","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/13506120802193720","article-title":"Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population","volume":"15","author":"Hellman","year":"2008","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0021","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/jmg.31.5.351","article-title":"Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate","volume":"31","author":"Holmgren","year":"1994","journal-title":"J Med Genet"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0022","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/13506129.2020.1841623","article-title":"New data on the genetic profile and penetrance of hereditary Val30Met transthyretin amyloidosis in Sweden","volume":"28","author":"Gorram","year":"2021","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0023","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jns.2008.02.019","article-title":"Epidemiology of familial amyloid polyneuropathy in Japan: identification of a novel endemic focus","volume":"270","author":"Kato-Motozaki","year":"2008","journal-title":"J Neurol Sci"},{"issue":"suppl 1","key":"10.1016\/j.amjcard.2022.09.011_bib0024","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/13506129.2012.670813","article-title":"Regional differences and similarities of FAP in Sweden","volume":"19","author":"Hellman","year":"2012","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0025","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/13506120903093944","article-title":"Parent-of-origin effect in transthyretin related amyloid polyneuropathy","volume":"16","author":"Bona\u00efti","year":"2009","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0026","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/ejhg.2010.36","article-title":"TTR familial amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin difference in penetrance?","volume":"18","author":"Bona\u00efti","year":"2010","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0027","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ahj.2010.02.006","article-title":"Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies","volume":"159","author":"Buxbaum","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0028","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2019.17935","article-title":"Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of African or Hispanic\/Latino ancestry","volume":"322","author":"Damrauer","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0029","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke statistics\u20142022 update: a report from the American Heart Association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0030","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002558","article-title":"Transthyretin cardiac amyloidosis in Black Americans","volume":"9","author":"Shah","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0031","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s10741-021-10164-z","article-title":"The genetics of cardiac amyloidosis","volume":"27","author":"Arno","year":"2022","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0032","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamacardio.2018.2093","article-title":"Geographic disparities in reported US amyloidosis mortality from 1979 to 2015: potential underdetection of cardiac amyloidosis","volume":"3","author":"Alexander","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0033","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jaccao.2021.07.002","article-title":"Regeneron Genetics Center, Tarrytown, New York, USA. Genomic screening for pathogenic transthyretin variants finds evidence of underdiagnosed amyloid cardiomyopathy from health records","volume":"3","author":"Carry","year":"2021","journal-title":"JACC Cardiooncol"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0034","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1126\/science.1062245","article-title":"Trans-suppression of misfolding in an amyloid disease","volume":"293","author":"Hammarstr\u00f6m","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0035","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1006\/jmbi.2000.4415","article-title":"Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution","volume":"306","author":"Sebasti\u00e3o","year":"2001","journal-title":"J Mol Biol"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0036","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0037","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/13506129.2017.1324418","article-title":"Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis","volume":"24","author":"Brown","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0038","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10897-005-9014-3","article-title":"A new definition of Genetic Counseling: National Society of Genetic Counselors\u2019 Task Force report","volume":"15","author":"Resta","year":"2006","journal-title":"J Genet Couns"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0039","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s10897-014-9728-1","article-title":"Conceptualizing genetic counseling as psychotherapy in the era of genomic medicine","volume":"23","author":"Austin","year":"2014","journal-title":"J Genet Couns"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0040","unstructured":"US Department of Labor. Frequently asked questions regarding the Genetic Information Nondiscrimination Act. Available at:https:\/\/www.dol.gov\/sites\/dolgov\/files\/ebsa\/about-ebsa\/our-activities\/resource-center\/faqs\/gina.pdf. Accessed on February 4, 2022."},{"key":"10.1016\/j.amjcard.2022.09.011_bib0041","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/ana.24972","article-title":"Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy","volume":"82","author":"Ebenezer","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0042","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10741-021-10143-4","article-title":"The use of diflunisal for transthyretin cardiac amyloidosis: a review","volume":"27","author":"Ibrahim","year":"2022","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.amjcard.2022.09.011_bib0043","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00392-012-0463-z","article-title":"Green tea halts progression of cardiac transthyretin amyloidosis: an observational report","volume":"101","author":"Kristen","year":"2012","journal-title":"Clin Res Cardiol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914922009985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914922009985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:07:31Z","timestamp":1762078051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914922009985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":43,"alternative-id":["S0002914922009985"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2022.09.011","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Counseling Family Members and Monitoring for Evidence of Disease in Asymptomatic Carriers of Amyloid Transthyretin Cardiac Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2022.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}